Potassium binder to help heart failure patients on mineralocorticoid receptor antagonists
Part of Heart & circulation clinical trials.
This trial tests whether a medication called sodium zirconium cyclosilicate can help older adults with heart failure safely take a higher dose of a mineralocorticoid receptor antagonist (MRA), a drug that can improve heart function but may raise potassium levels. The study aims to prevent dangerous high potassium levels while allowing the heart medication to work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 70 years old.
- You have heart failure, with your heart's pumping ability measured within the last 2 years.
- Your kidney function is at least 20 mL/min/1.73 m² (your doctor can check this).
- You have symptoms like shortness of breath or fatigue (NYHA class II to IV).
- You are already taking standard heart failure medications, such as ACE inhibitors, ARBs, ARNIs, beta blockers, or SGLT2 inhibitors.
- You are not currently taking an MRA (like spironolactone or eplerenone) or are taking a low dose (25 mg daily or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the best way to manage heart failure in older adults who also have kidney problems and high potassium levels. It compares different treatment strategies to see which one is safest and most effective.
This study compares two medicines, spironolactone and finerenone, to see which one manages potassium levels better in people with heart failure, type 2 diabetes, and kidney disease. Participants have high potassium levels, and the trial aims to find a safer way to manage this.
This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.
This trial tests a treatment intended to improve how heart muscle cells handle calcium, which may help heart failure symptoms and heart function. It is mainly for people with advanced heart failure and a low pumping strength of the heart.
This trial tests whether safely increasing the dose of standard heart failure medications can improve outcomes in people with a weak heart pump, while keeping a close eye on kidney function. It may be a good fit if you have heart failure with reduced ejection fraction and are not yet on the highest recommended doses of your medicines.
This trial tests a new medicine called finerenone to see if it can reduce heart scarring and improve heart function in people with a certain type of heart failure (preserved ejection fraction). If you qualify, you may help researchers learn if this treatment can help you feel better and stay out of the hospital.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.